AbbVie vs Gilead Sciences stock: the numbers side by side (October 2026)
How do AbbVie and Gilead Sciences compare?
| AbbVie ABBV | Gilead Sciences GILD | |
|---|---|---|
| Revenue growth | 8.6%2025 | 2.4%2025 |
| Operating margin | 24.6%2025 | 34.0%2025 |
| Free cash flow | 17,816US$ millions · 2025 | 9,456US$ millions · 2025 |
| Free cash flow yield | 3.5%Today (Oct 30, 2026) | 4.6%Today (Oct 29, 2026) |
| Dividend yield | 2.5%Today (Oct 30, 2026) | 2.0%Today (Oct 29, 2026) |
| P/E, last 12 months | 50.1xToday (Oct 30, 2026) | not meaningfulToday (Oct 29, 2026) |
| P/E, next 12 months | 17.9xToday (Oct 30, 2026) | 16.6xToday (Oct 29, 2026) |
| Weighted price forecast, about 1 year | 285.67 (+1 %)October 2027 | 161.11 (-1 %)October 2027 |
| Weighted price forecast, about 3 years | 311.73 (+15 %)October 2029 | 158.32 (+2 %)October 2029 |
Who leads on what?
| Leads | The lead is | |
|---|---|---|
| Revenue growth | AbbVie | The higher figure |
| Operating margin | Gilead Sciences | The higher figure |
| Free cash flow | AbbVie | The higher figure |
| Free cash flow yield | Gilead Sciences | The higher figure |
| Dividend yield | AbbVie | The higher figure |
| P/E, last 12 months | — | The lower figure |
| P/E, next 12 months | Gilead Sciences | The lower figure |
| Weighted price forecast, about 1 year | AbbVie | The higher weighted return |
| Weighted price forecast, about 3 years | AbbVie | The higher weighted return |
What does each company do?
AbbVie sells prescription medicines in immunology, neuroscience and oncology, along with medical-aesthetics products such as Botox Cosmetic and Juvéderm.
AbbVie (ABBV), from our memo of October 30, 2026 · AbbVie stock forecast
Gilead Sciences sells HIV treatments and prevention, liver-disease medicines, cancer therapies and other specialty drugs.
Gilead Sciences (GILD), from our memo of October 30, 2026 · Gilead Sciences stock forecast
How fast are AbbVie and Gilead Sciences growing, and what did their latest results show?
AbbVie’s revenue grew 8.6% in 2025; Gilead Sciences’ grew 2.4% in 2025.
The latest quarter confirms continued sales progress, but its earnings growth is amplified by a weak comparison.
AbbVie (ABBV), from our memo of October 30, 2026 · AbbVie earnings
How much cash do AbbVie and Gilead Sciences generate, and where does it go?
AbbVie’s free cash flow was US$17,816 million in 2025; Gilead Sciences’ was US$9,456 million in 2025. At AbbVie, the dividend yield was 2.5% on October 30, 2026; at Gilead Sciences, it was 2.0% on October 29, 2026.
AbbVie generates strong operating cash, but free cash flow is not all surplus cash for shareholders.
AbbVie (ABBV), from our memo of October 30, 2026 · AbbVie stock forecast
Free cash flow subtracts capital spending on property and equipment from operating cash. Gilead generated $9.5 billion of free cash flow in 2025, equal to 32.1% of revenue. The measure is useful for dividends, debt and deals, but it excludes acquisition payments and does not represent every investment needed to sustain a drug portfolio.
Gilead Sciences (GILD), from our memo of October 30, 2026 · Gilead Sciences stock forecast
What does an investor pay for AbbVie and Gilead Sciences today?
The shares of AbbVie were priced at 17.9x the next 12 months’ earnings on October 30, 2026; those of Gilead Sciences at 16.6x the next 12 months’ earnings on October 29, 2026. AbbVie’s free cash flow yield was 3.5% on October 30, 2026; Gilead Sciences’ was 4.6% on October 29, 2026.